Boston Biomedical, Inc. is a leading developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. As a fully integrated oncology drug research and development company, Boston Biomedical, Inc. has established a track record of accomplishments, including advancing the research and development of multiple compounds and clinical programs. The company’s range of expertise includes drug discovery, medicinal chemistry, preclinical development, pharmacology, pharmaceutical development, CMC (chemistry, manufacturing, and control), global clinical trials, regulatory affairs
Headquartered in Cambridge, Massachusetts, Boston Biomedical, Inc. is wholly owned by Sumitomo Dainippon Pharma Co., Ltd., a pharmaceutical company based in Japan. In 2017, Sumitomo Dainippon Pharma acquired Tolero Pharmaceuticals, a U.S.-based biotechnology company specializing in research and development of therapeutic agents in the areas of oncology and hematological disorders. This acquisition expanded Sumitomo Dainippon Pharma’s global oncology and hematology portfolios. Together, the companies – Sumitomo Dainippon Pharma Co., Ltd., Boston Biomedical and Tolero – work to expedite drug discovery, development
Industry veteran Patricia S. Andrews was appointed to the role of Chief Executive Officer in 2017. Since joining the company in 2013, Ms. Andrews has been a key driving force to lead the company forward into the next stage of growth and innovation through expanding its robust clinical pipeline, initiating additional clinical studies for its investigational compounds across multiple tumor types, and setting the foundation for future commercialization of late-stage compounds.
Edgar Braendle, MD,
Dee Mahoney, Senior Vice President
The company’s most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses.
Our most advanced research compound,
Recently, the Company advanced DSP-7888 (
With a robust pipeline across various stages of clinical development and multiple
Boston Biomedical, Inc. has created a unique corporate environment, leveraging its innovation-driven culture, scientific leadership, and drug development expertise to advance the development of novel therapeutics for patients with cancer. Click here to learn more about career opportunities.